Update on juvenile myasthenia gravis

Current Opinion in Pediatrics

Volumn 25, Issue 6, 2013, Pages 694-700

  Liew, Wendy K M ^a   Kang, Peter B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

acetylcholine receptor antibodies; intravenous immunoglobulin; juvenile myasthenia gravis; plasmapheresis; thymectomy

Indexed keywords

ACETYLCHOLINE; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE;

ABDOMINAL CRAMP; ANTIGENIC MODULATION; ARTIFICIAL VENTILATION; BREATHING MUSCLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; COHORT ANALYSIS; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DYSARTHRIA; DYSPHAGIA; EXPERIENCE; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; JUVENILE MYASTHENIA GRAVIS; LIMB WEAKNESS; MYASTHENIA GRAVIS; NASAL SPEECH; NERVE STIMULATION; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PATIENT REFERRAL; PEDIATRICS; PLASMAPHERESIS; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PTOSIS; REVIEW; THYMECTOMY; THYMOMA; TREATMENT OUTCOME; WEAKNESS;

AGE OF ONSET; CHILD; CHILD, PRESCHOOL; CHOLINESTERASE INHIBITORS; ELECTROMYOGRAPHY; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; INFANT; MALE; MYASTHENIA GRAVIS, NEONATAL; MYASTHENIC SYNDROMES, CONGENITAL; PLASMAPHERESIS; PYRIDOSTIGMINE BROMIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYMECTOMY;

EID: 84888127925     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328365ad16     Document Type: Review

References (38)

1. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology 2000; 107:504-510.
2. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;57:2122-2128.
3. Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery ofMuSK myasthenia gravis. J Anat 2013.
4. Jitpimolmard S, Taimkao S, Chotmongkol V, et al. Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients. J Med Assoc Thai.2006;89:68-71.
5. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with antimuscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry 2007; 78:417-418.
6. Seybold ME, Baergen RN, Nave B, Lindstrom JM. Antiacetylcholine-receptor antibody concentrations after thymectomy in patients with myasthenia gravis. BMJ 1978; 2:1051-1053.
7. Snead OC 3rd, Benton JW, Dwyer D, et al. Juvenile myasthenia gravis. Neurology 1980; 30 (7 Pt 1):732-739.
8. Pitt M. Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children. Dev Med Child Neurol 2008; 50:328-333.
9. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve.2009,39:423-431.
10. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68:837-841.
11. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; CD002277.
12. McMillan HJ, Darras BT, Kang PB. Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol 2011; 13:590-607.
13. Punga AR, Flink R, Askmark H, Stalberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006; 34:111-115.
14. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76:2017-2023.
15. Evoli A, Batocchi AP, Bartoccioni E, et al. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord 1998; 8:561-567.
16. Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol 2000;22:40-43.
17. Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 2006; 114:119-123.
18. Kaminski HJ, Cutter G, Ruff R. Practice parameters and focusing research: plasma exchange for myasthenia gravis. Muscle Nerve 2011; 43:625-626.
19. Mandawat A, Kaminski HJ, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010; 68:797-805.
20. Mandawat A, Kaminski HJ, Shaker ZA, et al. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve 2011;43:578-584.
21. Miller RG, Barohn RJ, Dubinsky R. Expanding the evidence base for therapeutics in myasthenia gravis. Ann Neurol 2010; 68:776-777.
22. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902.
23. Kang PB, Finkel RS. Myasthenia gravis. In FD Burg, JR Ingelfinger, RA Polin, AA Gershon, editors. Current Pediatric Therapy. 18th ed. Philadelphia Saunders Elsevier; 2006. pp. 1028-1033.
24. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012; 12:CD002277. This is a review of all randomized controlled trials examining the efficacy of intravenous immunoglobulin in the treatment of myasthenia gravis.
25. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; CD002828.
26. Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol 1997;244:515-520.
27. Adams C, Theodorescu D, Murphy EG, Shandling B. Thymectomy in juvenile myasthenia gravis. J Child Neurol 1990; 5:215-218.
28. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2000;55:7-15.
29. Christison-Lagay E, Dharia B, Vajsar J, Kim PC. Efficacy and safety of thoracoscopic thymectomy in the treatment of juvenile myasthenia gravis. Pediatr Surg Int 2013; 29:583-586.
30. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: disease severity and prognosis. Acta Neurol Scand Suppl 2006; 183:24-25.
31. Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: three case reports and a literature review. J Child Neurol 2009; 24:584-590.
32. Castro D, Derisavifard S, Anderson M, et al. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis 2013; 14:95-102.
33. Seybold ME. Thymectomy in childhood myasthenia gravis. Ann N Y Acad Sci,1998:841;731-741.
34. Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol 2009; 24:454-459.
35. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983; 13:504-510.
36. Guillermo GR, Tellez-Zenteno JF,Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand 2004; 109:217-221.
37. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005; 12:413-418.
38. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis 2011; 2011:404101.